Zymeworks: Early But Compelling Data, Large Biopharma Partners And A Potential June Catalyst

Barclays initiated coverage of Zymeworks Inc ZYME with an Overweight rating and price target of $20. The company released first-quarter earnings last week, reporting ($1.13) EPS on the quarter with revenue of $0.23 million.

Early-Stage, But Potentially Important

Zymeworks is a biopharma company focused on developing cancer treatments. Its most advanced asset is ZW25, an antibody currently being studied for the treatment of HER2+ cancers such as breast, gastric and ovarian.

Early data suggests efficacy and safety, and Barclays analyst Geoff Meacham, in a recent note, highlighted high unmet medical need for HER2+ cancer treatments.

Large Biopharma Partners

“Zymeworks also has a broader antibody platform, which is the basis for several collaboration agreements,” wrote Meacham. Another asset of note is ZW33, a bispecific antibody conjugate.

These agreements are with major players in the pharmaceutical sector, including GlaxoSmithKline plc (ADR) GSK, Eli Lilly and Co LLY and Merck & Co., Inc. MRK.

The analyst believes that sales could easily reach $1 billion if ZW25 or ZW33 are successful.

Catalysts To Look Out For

Meacham expects the upcoming American Society of Clinical Oncology meeting in June to be the nearest big driver of Zymeworks shares.

Clinical progression of ZW25 in the second half of fiscal 2017 and ZW33 in early 2018 will also impact shares.

Related Links:

The Next Steps For OncoCyte After Better-Than-Expected Data

Here's Why Wednesday Is The Next Big Catalyst For Puma Biotech

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: Analyst ColorBiotechEarningsLong IdeasNewsGuidanceHealth CarePrice TargetInitiationPreviewsEventsAnalyst RatingsTrading IdeasGeneralBarclayscancerGeoff MeachamZW25ZW33
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!